Hybridoma / Monoclonal Antibody Development
The art of creating hybridomas requires years of experience to be perfected. For more than 25 years QED has provided services to the scientific community, developing and producing monoclonal antibodies to diverse types of antigens including large and small peptides, proteins, haptens, carbohydrates, bacterial and viral antigens.
We appreciate that every Client’s requirements are unique, so our hybridoma development programs are never “cookbook”. We tailor programs specifically suited to client’s needs after discussing important features of your antigens, the antibodies and project deliverables.
Hybridoma / Monoclonal Antibody Development
A typical program is set up as follows:
Phase I: Immunization
| 5 mice |
- All immunizations and blood collections
- Monitoring serum antibody titers by ELISA
- Reports of ELISA results.
Estimated completion time: 10 weeks
Phase II: Fusion
| 6 x 96-well fusion plates |
- Fusion of immune mouse spleen cells to 2 different myeloma cell lines
- All cell culture activities required to generate monoclonal hybridoma cell lines
- Frozen vials of parental and subcloned hybridomas provided
Estimated completion time: 7-8 weeks
Phase III: Fusion Analysis (concurrent with Phase II)
| Characterization |
ELISA screening on 1 antigen (additional charge for screening on >1 antigen) of:
- Initial fusion plates
- Expanded positive parental hybridomas
- Initial subclone plates
- Expanded positive subclones
- Reports of screening results
- Isotyping of final subclone MAbs
Phase IV: Antibody Production
| Production |
- In vitroproduction 150ml culture per clone
or - Ascites production 5 mice per clone
Deliverables: culture supernatant or ascites fluid; MAb purification available
MAb purification available. Click here for antibody purification details.
Estimated completion time: 3-4 weeks
Don’t see the service that you need? Have Questions?
Call us at 800-929-2114 — we welcome the opportunity to support your projects.